NCT03205358View on ClinicalTrials.gov

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

PHASE2CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 19, 2015

Study Completion Date

August 19, 2015

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

0.5 milliliter (mL), Intramuscular (IM)

BIOLOGICAL

Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine

0.5 mL, IM

Trial Locations (8)

20520

Investigational Site Number 004, Turku

28100

Investigational Site Number 001, Pori

33100

Investigational Site Number 003, Tampere

90220

Investigational Site Number 008, Oulu

02230

Investigational Site Number 005, Espoo

00100

Investigational Site Number 006, Helsinki

00930

Investigational Site Number 002, Helsinki

04400

Investigational Site Number 007, Järvenpää

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03205358 - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers | Biotech Hunter | Biotech Hunter